National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Pembrolizuma (Keytruda®) as monotherapy is indicated for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.

NCPE Assessment Process Complete
Rapid review commissioned 19/11/2018
Rapid review completed 07/12/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard of care.